



**Ongoing Disclosure Notice**

**Disclosure of Directors and Officers Relevant Interests**

Section 19T(2), Securities Markets Act 1988

**A Details of director or officer**

Name of director or officer of public issuer:	John Andrew Bagnall
Name of public issuer:	Pharmacybrands Limited
Name of related body corporate (if applicable):	N/A
Position held in public issuer:	Director

**B Securities in public issuer or any related body corporate in which director or officer has relevant interest**

Number, class, and type of securities: <u>1</u>	39,285,925 ordinary shares
---	----------------------------

**C Nature of relevant interest and name of registered holder**

Nature of relevant interest in securities: <u>2</u>	Holder of all the shares in LPL Trustee Limited
Name of registered holder of securities <u>3</u>	LPL Trustee Limited

**D Details of acquisitions and disposals**

*If the relevant interest was acquired—*

Date of acquisition: <u>4</u>	19 & 20/06/2013
Consideration paid for acquisition: <u>5</u>	\$1,245,349

*If the relevant interest was disposed of—*

Date of disposal: <u>6</u>	NA
Consideration paid for disposal: <u>7</u>	NA

*Type of transaction*

Describe the arrangement pursuant to which, or the circumstances in which, the acquisition or disposal took place: 8

Acquisition of 949,199 ordinary shares by LPL Trustee Limited on reinvestment of dividends under the Dividend Reinvestment Plan of Pharmacybrands Limited. Shareholding now 30.82% of total shares.

E Total number of transactions this notice relates to: <u>9</u>	1
---	---

F Date of last disclosure notice (whether in form 1 or form 2) by the director or officer: <u>10</u>	25-Jun-13
--	-----------

**G Signature**

Signature of director or office:	
Date of signature:	

or

Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	26-Jun-13
Name and title of authorised person:	Vivek Singh, CFO Pharmacybrands Limited